The effects of fibrates on lipid metabolism and inflammation in type 2 diabetes

Abstract

Type 2 diabetes is associated with a cluster of cardiovascular risk factors that together promote macrovascular and microvascular disease. An atherogenic dyslipidaemia, characterised by an increase in serum triglyceride-rich lipoproteins, a decrease in plasma levels of high-density lipoprotein cholesterol (HDL-C) and increased prevalence of small, dense low-density lipoprotein (LDL) particles (although LDL-C levels are normal or only modestly elevated), as well as chronic inflammation, play key roles in the pathogenesis of diabetes-related complications. As peroxisome proliferator-activated receptor a agonists, the fibrates exert an integrated action to favour normalisation of lipid metabolism, cholesterol homeostasis and reverse cholesterol transport, inflammation and haemostasis, suggesting potential efficacy in preventing vascular complications of diabetes. By synergistic therapeutic targeting of abnormalities in lipid metabolism and inflammation, fenofi-brate can promote anti-atherogenic effects at the arterial wall, as demonstrated in the Diabetes Atherosclerosis Intervention Study (DAIS), and reduction of total cardiovascular events, as shown in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial.

Keywords

type 2 diabetes lipid metabolism inflammation vascular complications

References

Kannel WB. Lipids

, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J1985;110:1100–07.

Stamler J

Vaccaro O

Neaton JD

et al.

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993;16:434–44.

Guerin M

Le Goff W

Lassel T

et al.

Proatherogenic role of elevated cholesteryl ester transfer from HDL to VLDL1 and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol2001;21:282–8.

Chait A

Barzg RL

Tribble DL

et al.

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med1993;94:350–6.

Galeano NF

Milne R

Marcel YL

et al.

Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem1994;269:511–19.

Nigon F

Lesnik P

Rouis RM

Chapman MJ

. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res1991;32:1741–53.

Chapman MJ.

Atherogenicity of low-density lipoproteins: mechanisms. In:

Barter PJ

Rye KA

, editors. Plasma lipids and their role in disease. Taylor and Francis, Abingdon, UK, 1999:69–84.

Lamarche B

Rashid S

Lewis GF

. HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta1999;286:145–61.

Van Eckardstein A

Nofer JR

Assmann G.

High density lipoproteins and atherosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Atheroscler Thromb Vasc Biol2001;21:13–27.

10.

Dzau VJ.

Atherosclerosis and hypertension: mechanisms and interrelationships. J Cardiovasc Pharmacol1990;15 (suppl 5):S59–S64.

11.

Wilson AM

Ryan MC

Boyle AJ

. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol2006;106:291–7.

12.

Lobbes MB

Lutgens E

Heeneman S

et al.

Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis2006;187:18–25.

13.

Juhan-Vague I

Alessi MC

Mavri A

et al.

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost2003;1:1575–9.

14.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP

. Expert Panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III). JAMA2001;285:2486–97.

15.

Birjmohun RS

Hutten BA

Kastelein JJP

et al

. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol2005;45:185–97.

16.

Chapman MJ.

Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis2003;171:1–13.

17.

Fazio S

Linton MF

. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atherosclerosis Rep2004;6:148–57.

18.

Staels B

Dallongeville J

Auwerx J

et al.

Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation1998;98:2088–93.

19.

Willson TM

Brown PJ

Sternbach DD

et al.

The PPARs: from receptors to drug discovery. J Med Chem2000;22:717–26.

20.

Forcheron F

Cachefo A

Thevenon S

et al.

Mechanisms of the triglyc-eride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes2002;51:3486–91.

21.

Feher MD

Caslake M

Foxton J

et al.

Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev1999;15:395–9.

22.

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes

. the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001;357:905–10.

23.

Vakkilainen J

Steiner G

Ansquer JC

et al.

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Study (DAIS). Circulation2003;107:1733–7.

24.

Barbier O

Pineda Torra I

Dugay Y

et al.

Pleiotrophic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol2002;22:717–26.

25.

Devchand P

Keller H

Peters J

et al.

The PPARα-leucotriene B4 pathway to inflammation control. Nature1996;384:39–43.

26.

Staels B

Koenig W

Habib A

et al.

Activation of human aortic smooth muscle cells is inhibited by PPARa but not by PPAR activators. Nature1998;393:790–3.

27.

Marx M

Sukhova GK

Collins T

et al.

PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation1999;99:3125–31.

28.

Schonfeld G.

The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis1994;111:161–74.

29.

Hamsten A.

The hemostatic system and CAD. Thromb Res1993;70:1–38.

30.

Brownlee M.

Banting Lecture 2004. The pathobiology of diabetic complications. A unifying mechanism. Diabetes2005;54:1615–25.

31.

Koh KK

Han SW

Quon MJ

et al.

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care2005;28:1419–24.

32.

The FIELD study investigators

. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:1849–61.